Special developments include the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9‐based gene therapy NTLA‐2002, which targets the plasma kallikrein gene KLKB1 and is intended to be used for HAE prophylaxis.81 Here, KLK4 is linked to hereditary angioedema.